Could a vitamin e boost chemo for advanced colon cancer?

NCT ID NCT04245865

Ongoing Disease control Sponsor: Vejle Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding tocotrienol, a form of vitamin E, to standard chemotherapy and bevacizumab can improve treatment and reduce side effects in people with metastatic colorectal cancer. About 83 participants will be randomly assigned to receive either tocotrienol or a placebo alongside their regular therapy for up to six months. The main goal is to see how many patients remain free of cancer progression at six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tocotrienol (a form of vitamin E) taken as a dietary supplement
What this could lead to: If it works, this could point toward a way to make standard chemotherapy and bevacizumab more effective and less toxic for people with metastatic colorectal cancer.
What could go wrong: This is a small, early-phase trial with only 83 participants, so results may not apply widely. Tocotrienol is a supplement, not a proven cancer drug, and may not improve outcomes or reduce side effects as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Department of Oncology, Vejle Hospital

Vejle, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.